MedTrace Logo

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2015-04-29

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

liposomal daunorubicin citrate

40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • Juan Carlos Ramos, MD · University of Miami Sylvester Comprehensive Cancer Center

  • Dirk Dittmer, PhD · UNC Lineberger Comprehensive Cancer Center

  • Tamara Newman Lobato Souza · Instituto De Infectologia Emilio Ribas Hospital

  • Luis Carlos Pereira, MD · Instituto De Infectologia Emilio Ribas Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2010-11-30
Completion
2011-11-30

Countries

  • United States
  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427414 on ClinicalTrials.gov